Medtronic (MDT) just reported new real world results from its SPYRAL AFFIRM study and secured an FDA label update for the Symplicity Spyral renal denervation system, which is sharpening investor focus on its hypertension franchise.
Those clinical wins landed as Medtronic’s share price has been rebuilding momentum, with a 30 day share price return of 19.1% and a 90 day gain of 16.8% off a last close of US$101.80.
Over a longer stretch, total shareholder return of 14.1% over one year and 58.9% across three years suggests investors have already been rewarded. In that context, the recent SPYRAL AFFIRM data and FDA label change appear more like fresh fuel for an existing hypertension thesis than the start of a completely new story.
Scan for other hypertension and cardiovascular device stocks showing similar real world catalysts and price momentum by running the curated 35 healthcare AI stocks alongside Medtronic in your research.
Medtronic has already delivered strong multi year returns and a sharp recent rebound in the share price. The key question now is whether the valuation still leaves meaningful upside potential, or if most of the gain is already on the table.
Most Popular Narrative: 11.8% Undervalued
Medtronic is pegged with a fair value of $115.38 according to the most followed narrative, which sits above the recent $101.80 share price and frames the hypertension news against a broader re rating story.
The phrase "inflection point" or its equivalents have orbited Medtronic's transcript language for several quarters. This quarter, management moved to secure the claim. Martha's closing remarks to the analyst who asked whether the "mid-single-digit revenue grower, high single-digit EPS" characterization of Medtronic still holds: "Clearly, we have aspirations for higher growth than we've done historically... we're not satisfied with that." The framing is not a promise of specific targets, Investor Day in December is where those will be disclosed, but it is the first time management has used analyst-facing language to explicitly distance the company from its own historical growth ceiling.
See why 12 investors see Medtronic as 12% undervalued.
According to LunaRodas, who authored the narrative, that gap between price and fair value is anchored in a mix of execution and repositioning rather than a single product win. The write up points to 13.7% reported organic growth in fiscal Q1 2027, high growth pockets in Cardiac Ablation Solutions and Cranial and Spinal Technologies, and margin guidance that is edging higher even as management reinvests some of the upside.
The same narrative also flags trade offs that matter for anyone thinking about valuation. Operating margin expansion has been guided at approximately 50 basis points instead of 60 basis points, tariff costs have shifted from a structural talking point to something more managed, and robotics in soft tissue surgery is being reframed as a portfolio with Hugo and the Cornerstone Sentire system rather than a one platform bet. All of that sits alongside a planned MiniMed separation that management expects to lift gross and operating margins for the remaining group.
Against that backdrop, Simply Wall St data points to a fair value P/E ratio of 32x for Medtronic versus an actual multiple of 23.8x at the last close. It also indicates a DCF based future cash flow value estimate of $111.26 per share. The narrative fair value of $115.38 suggests a similar conclusion: that the current price embeds more modest expectations than those implied by that earnings and cash flow work.
Result: Fair Value of $115.38 (UNDERVALUED)
Still, if Medtronic stumbles on MiniMed separation timing or fails to sustain recent organic growth, that 11.8% undervaluation story could unravel quickly.
Find out about the key risks to this Medtronic narrative.
Next Steps
That 11.8% undervalued narrative is only one way to read Medtronic. Act quickly, review the full breakdown, and weigh the 5 key rewards.
Looking for more investment ideas beyond Medtronic?
If you stop with Medtronic, you risk missing other opportunities that fit your style, so widen your search now using focused screeners built for investors like you.
- Target stability first and cut portfolio stress by scanning a 29 resilient stocks with low risk scores that score well on resilience and lower risk profiles.
- Hunt for value gaps by reviewing a 39 high quality undervalued stocks that pair solid fundamentals with prices that may not fully reflect their strengths.
- Build a watchlist of future leaders by combing through a 19 high quality undiscovered gems with quality metrics that many investors are still overlooking.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com